For healthcare professionals. Compounded preparations are dispensed on a doctor’s prescription.
Short answer: Trials pairing topical finasteride with minoxidil in male androgenetic alopecia report mixed results. One 24-week trial reported greater hair density gains with the combined solution than minoxidil alone, while a 12-week trial found no difference in hair density change. Compounded combinations are prepared on a registered doctor’s prescription for one named patient, under Good Compounding Practice (GCP).

Why the combination is being studied
Oral finasteride and topical minoxidil are the treatments the authors of a 2025 randomised trial describe as currently FDA-approved for androgenetic alopecia. They describe topical finasteride as a potential alternative with similar efficacy and fewer systemic side effects (Lubis et al., Archives of Dermatological Research, 2025; PMID 40208341). Whether adding topical finasteride to minoxidil adds benefit over minoxidil alone is the question the trials below address.
What the trials show
Three records bear on the combination in men. They differ in strength, comparator, duration and outcome, so they should be read side by side rather than pooled in the head.
| Study | Participants and design | Composition compared | Duration | Outcome reported in the abstract |
|---|---|---|---|---|
| Suchonwanit et al., J Eur Acad Dermatol Venereol, 2018; PMID 29972712 | 40 men aged 18 to 60 years; randomised, double-blind | 0.25% finasteride admixed with 3% minoxidil solution vs 3% minoxidil solution | 24 weeks | Combined solution significantly superior to minoxidil alone in hair density, hair diameter and global photographic assessment |
| Lubis et al., Arch Dermatol Res, 2025; PMID 40208341 | 40 subjects, 2 dropped out of the treatment group; randomised controlled trial | 0.1% finasteride with 5% minoxidil vs 5% minoxidil | 12 weeks | No differences between groups; similar safety and effectiveness for hair density and diameter |
| Chen et al., Aesthetic Plast Surg, 2020; PMID 32166351 | Meta-analysis of 5 randomised controlled trials | Finasteride combined with topical minoxidil vs either agent alone | Not stated in abstract | Higher global photographic evaluation score; no significant difference in hair density change or adverse events |
The 2025 trial, run at a lower finasteride strength and a shorter duration, reported no difference between the combination and minoxidil alone (PMID 40208341). The 2020 meta-analysis reports a benefit on the global photographic score and no difference on hair density change (PMID 32166351). The composition figures in the table are those of the trials. They are not a recommended strength for any patient.
The evidence is limited. The two trials each enrolled about 40 men, the meta-analysis pools five trials with differing comparators, and the 2025 trial’s result runs against the 2018 result on the same comparison. A prescriber should not expect the magnitude of the 2018 result to apply to every patient.
Safety points the trials record
The 2018 trial reported no systemic adverse events in either group (PMID 29972712). The 2025 trial reported that systemic adverse events in the treatment arm included mild erectile dysfunction and chest pain, and that one treatment-arm patient had contact dermatitis (PMID 40208341). Whether a named patient needs monitoring is the prescribing doctor’s decision.
What the prescription must specify
A compounded combination is prepared for one named patient on a prescription. Lynnity prepares the combination as a topical liquid, serum or cream under Good Compounding Practice (GCP). The trials cited here do not establish a strength that suits any individual, so strength, quantity and directions are the prescriber’s decision.
Why a compounded form exists
The evidence above does not show that a compounded combination performs better than a commercially available one, and no study cited here compares them.
How to prescribe
A registered doctor writes the prescription. The prescription must state the active or actives, strength of each, form (topical liquid, serum or cream), quantity, directions, the named patient and the prescriber’s details.
To send a prescription or to discuss a named patient’s case, contact Vitthia Rama Murti, RPh (RPh 15632) through the Lynnity contact page. To speak with a Lynnity pharmacist about a combination preparation, use the same route.
Reviewed by Vitthia Rama Murti, RPh (RPh 15632).
Related reading: Lynnity’s compounded hair loss treatment page, compounded topical finasteride–minoxidil evidence and referral pathways, compounded hair-loss formulations for clinics, and minoxidil vehicle choice for KL hair clinics. Lynnity’s laboratory is described on the GCP laboratory page.
Frequently asked questions
Does topical finasteride with minoxidil work better than minoxidil alone?
The trials disagree. A 2018 randomised trial of 40 men reported significantly greater hair density gains with the combined solution than with minoxidil alone at 24 weeks (PMID 29972712). A 2025 randomised trial of 40 subjects reported no difference in hair density change between the combination and minoxidil alone at 12 weeks (PMID 40208341). A 2020 meta-analysis reported higher global photographic scores with combination therapy (PMID 32166351).
What must a prescription state for a compounded combination?
It must state each active and its strength, the form (topical liquid, serum or cream), the quantity, the directions, the named patient and the prescriber’s details. The strength and directions are the prescriber’s decision. The trials cited here do not establish a strength suited to any individual patient.
What side effects did the trials report?
The 2018 trial reported no systemic adverse events in either group (PMID 29972712). The 2025 trial reported mild erectile dysfunction and chest pain in the treatment arm and one case of contact dermatitis (PMID 40208341).

